<i>RET</i> Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer - Concepedia

Concepedia

Publication | Closed Access

<i>RET</i> Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer

543

Citations

26

References

2012

Year

Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,

Journal of Clinical Oncology

Abstract

RET fusion occurs in 1.4% of NSCLCs and 1.7% of lung adenocarcinomas and has identifiable clinicopathologic characteristics, warranting further clinical consideration and targeted therapy investigation.

References

	Year	Citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, New England Journal of Medicine	2004	11.4K
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Science	2004	9.4K
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer Manabu Soda, Young Lim Choi, Munehiro Enomoto, Nature OncologyNon-small-cell Lung CancerEml4–alk Fusion GeneMedicineCancer Cell Biology	2007	5.4K
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, New England Journal of Medicine	2010	4.5K
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib William Pao, Vincent A. Miller, Maureen F. Zakowski, Proceedings of the National Academy of Sciences	2004	4.3K
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou, Journal of Clinical Oncology	2012	1.5K
RET, ROS1 and ALK fusions in lung cancer Kengo Takeuchi, Manabu Soda, Yuki Togashi, Nature Medicine OncologyMedicineCancer GeneticsCancer BiologyCell Biology	2012	1.3K
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas Michèle Grieco, Massimo Santoro, Maria Teresa Berlingieri, Cell Oncogenic AgentThyroid DiseasePathologyNovel Rearranged FormRet Proto-oncogene	1990	957
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, The Lancet Oncology Overall SurvivalAlk Gene RearrangementMedicineRetrospective AnalysisPathology	2011	880
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies Doron Lipson, Marzia Capelletti, Roman Yelensky, Nature Medicine Tumor BiologyRadiation OncologyLung Cancer BiopsiesOncologyNew Alk	2012	860

Page 1